The Prognostic Factors for AML Children with CBFβ/MYH11 Positive.
10.19746/j.cnki.issn.1009-2137.2021.02.010
- Author:
Min YAN
1
;
Fu-Xing SONG
2
;
Jun LU
3
Author Information
1. Department of Pediatrics Jinan City People's Hospital, Jinan 271199, Shandong Province, China,E-mail: chizunv05@163.com.
2. Department of Pediatrics Jinan City People's Hospital, Jinan 271199, Shandong Province, China.
3. Department of Hematology Jinan City People's Hospital, Jinan 271199, Shandong Province, China.
- Publication Type:Journal Article
- MeSH:
Child;
Chromosome Inversion;
Genotype;
Humans;
Leukemia, Myeloid, Acute/genetics*;
Myosin Heavy Chains;
Oncogene Proteins, Fusion;
Prognosis
- From:
Journal of Experimental Hematology
2021;29(2):369-373
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze the prognostic factors of AML children with CBFβ/MYH11 positive.
METHODS:Twenty-eight children with CBFβ/MYH11 positive treated in our hospital from May 2012 to June 2018 were selected, the clinical data and curative were analyzed and evaluated.
RESULTS:Five-year OS and 5-year EFS rate of CBFβ/MYH11 positive AML children was 76.8% and 64.0% efficacy, respectively. Univariate analysis results showed that the OS rate of CBFβ/MYH11 positive AML children with WBC<60.0×10
CONCLUSION:WBC level and XRCC-Thr241Met genotype at initial diagnosis are the major affecting factors for prognosis of AML children with CBFβ/MYH11 positive.
